TGTX - Insider Transaction: Sagar Lonial Sells $432K Worth Of TG Therapeutics Shares | Benzinga
Disclosed on June 20, Sagar Lonial, Director at TG Therapeutics (NASDAQ:TGTX), executed a substantial insider sell as per the latest SEC filing.
What Happened: Lonial's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 25,933 shares of TG Therapeutics. The total transaction value is $432,888.
During Friday's morning session, TG Therapeutics shares up by 0.24%, currently priced at $17.02.
Discovering TG Therapeutics: A Closer Look
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
TG Therapeutics: Delving into Financials
Revenue Growth: TG Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 713.46%. This indicates a notable increase in the company's top-line earnings. In comparison to ...